Substance / Medication

Telavancin

Overview

Active Ingredient
telavancin
RxNorm CUI
473837

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

3 trials linked to this intervention

3
Total Trials
1
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis.
Polyzos Konstantinos A, Mavros Michael N, Vardakas Konstantinos Z et al. · PLoS One · 2012
PMID: 22916113Meta-AnalysisFull text (PMC)
Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections.
Stryjewski Martin E, Barriere Steven L, O'Riordan William et al. · J Antimicrob Chemother · 2012
PMID: 22416054Meta-Analysis
Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects.
Wong Shekman L, Barriere Steven L, Kitt Michael M et al. · J Antimicrob Chemother · 2008
PMID: 18586659RCT
Real-world use of telavancin in the treatment of osteomyelitis.
Saravolatz Louis D, Cleveland Kerry O, Rikabi Khalid et al. · Diagn Microbiol Infect Dis · 2019
PMID: 31256939Observational
Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides.
Al Jalali Valentin, Zeitlinger Markus · Clin Pharmacokinet · 2018
PMID: 29332251ObservationalFull text (PMC)
Telavancin for refractory MRSA bacteraemia in intermittent haemodialysis recipients.
Britt Nicholas S, Tirmizi Samad, Ritchie David J et al. · J Antimicrob Chemother · 2018
PMID: 29244141ObservationalFull text (PMC)
Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014).
Duncan Leonard R, Sader Helio S, Smart Jennifer I et al. · J Glob Antimicrob Resist · 2017
PMID: 28735051Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Telavancin (substance)
SNOMED CT
443553004
UMLS CUI
C1453642
RxNorm CUI
473837

Clinical Data

This intervention maps to 10 entities in the Healos knowledge graph.

5
Conditions
2
Biomarkers
2
Specialists
0
Symptoms
3
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.